Tourisme de croisière et industrie de la croisière

International audienceThis paper proposes a reflection on the cruise industry, the importance and scope of this industry. One of the objectives is to examine in particular the relationship between cruise lines and ports that receive cruises and excursionists. The cruise product built from the 1970s engendred a specific mass tourism. And the boat is both the means of transport and the destination. The stops have a secondary role in this logic that favors gigantism, standardization and uniformity. While gigantism known some limits, cruise products reconstructs itself spatially and innovative segments of the high-end and luxury.Ce texte pose les bases d’une réflexion sur les fondements de l’industrie de la croisière et sur l’importance et la portée de ce secteur d’activité. Il s’interroge notamment sur les relations entre les compagnies de croisières et le port récepteur des croisiéristes lors des excursions. Le produit croisière construit à partir des années 1970 a donné naissance à un tourisme de masse spécifique ; le bateau est à la fois le moyen de transport et la destination. Les escales n’ont qu’un rôle secondaire dans cette logique qui privilégie le gigantisme, la standardisation et l’uniformisation. Alors que le gigantisme touche certaines limites, l’offre croisière se recompose spatialement et innove sur les segments du haut de gamme et du luxe

Répartition du tourisme de croisière dans la Caraïbe : quels déterminants ?

La croissance continue de la fréquentation de croisière dans l’espace caribéen constitue un fait majeur du tourisme international des quatre dernières décennies. La diminution des croisiéristes depuis 2004, la forte et stable concentration sur les dix dernières années et le basculement vers l’ouest Caribéen sont aussi les caractères essentiels de la croisière caribéenne. La répartition intra-caribéenne du flux d’excursionnistes de croisière n’a pas à ce jour fait l’objet d’analyses. L’éloignement relativement à la Floride et le revenu des compagnies déterminent la concentration de la fréquentation de croisière dans la zone. L’article confirme le comportement d’offre des compagnies de croisière comme le facteur structurant de la « spatialisation » de la croisière dans la Caraïbe. Il enrichit la panoplie des politiques économiques des espaces de réception d’un nouvel outil : la compréhension du comportement des compagnies.concentration, répartition, éloignement, revenu, comportement d’offre

Le tourisme de croisière dans le monde : permanences et recompositions

International audienceCruise tourism is a sector that is rapidly expanding (16 million passengers in 2011). Today, cruising remains an essentially American affair, dominated by North American clients whose preferred destination is the Caribbean Sea. American cruise circuits continue to extend and diversify from the Panama Canal to the edge of Alaska. Meanwhile, cruises strengthen their position on the Mediterranean and Baltic Seas and has launched in East Asia from shores of the South China Sea to major rivers. Between continuity and recomposition, the cruise industry faces several challenges such as the limits of overcapacity (more than 6,000 passengers on board), its relationship with the host territories (ports of call), and the renewal of the “cruise” products.Le tourisme de croisière est un secteur d’activité en pleine expansion (16 millions de passagers en 2011). De nos jours, la croisière reste encore une affaire essentiellement américaine, dominée par les clientèles nord-américaines, et dont le champ spatial privilégié est la mer des Caraïbes. Les circuits américains de la croisière s’étendent et se diversifient, du canal du Panama aux confins de l’Alaska. Parallèlement, la croisière conforte sa position sur les mers méditerranéenne et baltique et se déploie en Asie orientale, des rivages de la mer de Chine aux grands fleuves. Entre permanences et recompositions, l’industrie de la croisière doit relever plusieurs défis tels que les limites du gigantisme (plus de 6 000 passagers à bord), ses relations avec les territoires d’accueil (les ports d’escales), le renouvellement du produit « croisière »

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival